Hospital
Pih Health Whittier Hospital
Pih Health Whittier Hospital was paid $26.12M by Medicaid between Jan 2018 and Nov 2024, across 284 billing codes. Its largest line is 0450, Emergency room services — 18% of everything it billed.
33Billing provider infoPIH HEALTH WHITTIER HOSPITAL
WHITTIER, CA 90602
WHITTIER, CA 90602
33aNPI1043215379assigned 06/14/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$26.12M
24GClaims1,117,981
24DCodes billed284
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#101 of 410
Median peer was paid$6.90M
This provider vs. median3.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 176,122 | $3.46M | |
| 2019 | 171,238 | $4.76M | |
| 2020 | 133,524 | $3.38M | |
| 2021 | 147,164 | $3.82M | |
| 2022 | 156,555 | $3.93M | |
| 2023 | 184,529 | $4.05M | |
| 2024incomplete | 148,849 | $2.71M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 18% | 125,607 | 111,523 | $4.64M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.9% | 10,510 | 10,065 | $1.53M |
| 0270 | 5.8% | 32,035 | 18,459 | $1.51M | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.9% | 24,152 | 21,952 | $1.01M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.6% | 10,432 | 9,954 | $950K |
| J3490 | Unclassified drugs | 3.0% | 53,808 | 29,923 | $786K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.8% | 7,379 | 6,898 | $738K |
| 0214 | 2.4% | 269 | 233 | $619K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.4% | 12,714 | 11,389 | $618K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.4% | 34,787 | 31,250 | $618K |
| 0250 | 2.0% | 26,918 | 16,326 | $531K | |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.0% | 5,214 | 4,859 | $521K |
272 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.9% | 18,283 | $494K |
| Z7502 | 1.8% | 13,039 | $465K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.6% | 65,529 | $415K |
| 93975 | 1.4% | 2,884 | $373K | |
| 71045 | Radiologic examination, chest; single view | 1.4% | 34,418 | $372K |
| 0300 | 1.4% | 1,045 | $365K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 69,409 | $360K |
| 99285 | Emergency room visit (most serious) | 1.4% | 1,188 | $353K |
| 0360 | 1.3% | 2,775 | $336K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 6,517 | $324K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.2% | 9,170 | $323K |
| 99199 | Unlisted special service, procedure or report | 1.2% | 10,379 | $314K |
| 0121 | <1% | 131 | $260K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,037 | $241K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,837 | $226K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,772 | $215K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,385 | $212K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,498 | $201K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,365 | $187K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 10,597 | $183K |
| 0762 | <1% | 2,303 | $168K | |
| 84484 | <1% | 22,760 | $158K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 10,119 | $150K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,309 | $145K |
| 80076 | <1% | 22,113 | $141K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 14,749 | $127K |
| 76830 | Ultrasound, transvaginal | <1% | 2,769 | $126K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,925 | $119K |
| 76801 | <1% | 3,163 | $117K | |
| 0279 | <1% | 2,617 | $116K | |
| 93970 | <1% | 1,219 | $115K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 355 | $114K |
| 93971 | <1% | 1,634 | $113K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,521 | $107K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,673 | $100K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 785 | $99K |
| 87634 | <1% | 2,517 | $94K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 14,522 | $92K |
| 83690 | <1% | 18,718 | $86K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 15,073 | $85K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,549 | $84K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,070 | $84K |
| 84703 | <1% | 19,340 | $82K | |
| 0160 | <1% | 3,035 | $80K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 404 | $79K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,638 | $78K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,030 | $75K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 12,121 | $73K |
| 81003 | <1% | 38,909 | $69K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,594 | $69K |
| 73564 | <1% | 3,129 | $68K | |
| 0301 | <1% | 1,160 | $65K | |
| E0114 | Crutches underarm, other than wood, adjustable or fixed, pair, with pads, tips and handgrips | <1% | 2,448 | $61K |
| 0710 | <1% | 2,109 | $60K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,732 | $59K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,953 | $57K |
| 90715 | <1% | 1,903 | $55K | |
| Z9725 | <1% | 1,252 | $54K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 1,202 | $53K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 8,203 | $51K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,438 | $50K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,434 | $50K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,142 | $50K |
| 72100 | <1% | 2,375 | $50K | |
| 73610 | <1% | 2,832 | $50K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,479 | $49K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 12,599 | $49K |
| 83880 | <1% | 2,824 | $49K | |
| 73630 | <1% | 2,843 | $47K | |
| L3650 | Shoulder orthosis, figure of eight design abduction restrainer, prefabricated, off-the-shelf | <1% | 1,554 | $46K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,809 | $43K |
| 73030 | <1% | 2,504 | $42K | |
| 73130 | <1% | 2,161 | $40K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,182 | $38K |
| 0320 | <1% | 977 | $37K | |
| 87040 | <1% | 4,414 | $37K | |
| 73110 | <1% | 1,842 | $37K | |
| 70486 | <1% | 430 | $37K | |
| 80053 | Comprehensive metabolic panel | <1% | 2,296 | $35K |
| 84702 | <1% | 3,247 | $29K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,168 | $28K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,397 | $28K |
| 96367 | <1% | 942 | $27K | |
| 83735 | <1% | 6,591 | $27K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,049 | $26K |
| 97161 | <1% | 1,829 | $26K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 228 | $25K |
| 81025 | <1% | 5,753 | $24K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,760 | $24K |
| 73080 | <1% | 1,301 | $23K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,754 | $23K |
| 87186 | <1% | 3,924 | $22K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 850 | $22K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 680 | $22K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 4,097 | $20K |
| 83605 | <1% | 2,991 | $20K | |
| 82805 | <1% | 729 | $19K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 296 | $18K |
| 36000 | <1% | 4,679 | $17K | |
| 82947 | <1% | 5,957 | $17K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,034 | $17K |
| 71250 | <1% | 312 | $17K | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 437 | $16K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 928 | $16K |
| 84100 | <1% | 5,786 | $16K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 758 | $16K |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 310 | $16K |
| 85730 | <1% | 4,010 | $15K | |
| A6403 | Gauze, non-impregnated, sterile, pad size more than 16 sq. in. less than or equal to 48 sq. in., without adhesive border, each dressing | <1% | 861 | $15K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,806 | $15K |
| 73502 | <1% | 773 | $15K | |
| 99000 | <1% | 4,938 | $14K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,349 | $14K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 149 | $14K |
| 27502 | <1% | 131 | $14K | |
| 82948 | <1% | 4,149 | $13K | |
| 85610 | <1% | 5,073 | $13K | |
| 10060 | <1% | 1,058 | $13K | |
| 84439 | <1% | 2,171 | $12K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,927 | $12K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 231 | $12K |
| 71101 | <1% | 428 | $12K | |
| 12001 | <1% | 764 | $11K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,600 | $11K |
| 0730 | <1% | 484 | $10K | |
| 73140 | <1% | 894 | $10K | |
| 73590 | <1% | 694 | $9K | |
| 76870 | <1% | 323 | $9K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,077 | $9K |
| Z7610 | <1% | 1,212 | $9K | |
| 29125 | <1% | 801 | $9K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 381 | $9K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,409 | $9K |
| 87807 | <1% | 1,115 | $9K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 92 | $9K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,075 | $9K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,952 | $9K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,872 | $8K |
| 77066 | Tomosynthesis, mammo | <1% | 539 | $8K |
| 87077 | <1% | 1,762 | $8K | |
| 86901 | <1% | 3,320 | $8K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 900 | $8K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,764 | $8K |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 59 | $8K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,858 | $8K |
| 86900 | <1% | 3,319 | $8K | |
| 87581 | <1% | 400 | $8K | |
| 87486 | <1% | 400 | $8K | |
| A9270 | Non-covered item or service | <1% | 3,566 | $8K |
| J1815 | Injection, insulin, per 5 units | <1% | 1,798 | $7K |
| 70496 | <1% | 88 | $7K | |
| 74018 | <1% | 648 | $7K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 390 | $7K |
| 72050 | <1% | 284 | $7K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 126 | $7K |
| 87081 | <1% | 1,698 | $7K | |
| 99070 | <1% | 1,540 | $7K | |
| 85378 | <1% | 1,210 | $7K | |
| 86140 | <1% | 1,951 | $6K | |
| 73090 | <1% | 394 | $6K | |
| 70498 | <1% | 45 | $6K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 77 | $6K |
| 76642 | <1% | 669 | $6K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,065 | $6K |
| 80061 | Lipid panel | <1% | 1,044 | $6K |
| 87210 | <1% | 1,672 | $5K | |
| 85027 | <1% | 1,541 | $5K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 660 | $5K |
| 72072 | <1% | 203 | $5K | |
| 0370 | <1% | 376 | $5K | |
| 76813 | <1% | 174 | $4K | |
| 73562 | <1% | 303 | $4K | |
| 76775 | <1% | 69 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 734 | $3K |
| 0294 | <1% | 580 | $3K | |
| 12011 | <1% | 233 | $3K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 94 | $3K |
| 86850 | <1% | 883 | $3K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 94 | $3K |
| G0378 | Hospital observation service, per hour | <1% | 65 | $3K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 81 | $3K |
| A4649 | Surgical supply; miscellaneous | <1% | 1,542 | $2K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 59 | $2K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,767 | $2K |
| 0637 | <1% | 1,021 | $2K | |
| 72040 | <1% | 91 | $2K | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 163 | $2K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 312 | $2K |
| 0272 | <1% | 1,080 | $2K | |
| 0760 | <1% | 561 | $2K | |
| 77336 | <1% | 31 | $2K | |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | <1% | 12 | $2K |
| 29515 | <1% | 343 | $2K | |
| 93017 | <1% | 94 | $2K | |
| 96415 | <1% | 280 | $2K | |
| 82010 | <1% | 283 | $2K | |
| 71010 | <1% | 126 | $2K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 78 | $1K |
| A4217 | Sterile water/saline, 500 ml | <1% | 144 | $1K |
| 87070 | <1% | 269 | $1K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 27 | $1K |
| 82550 | <1% | 307 | $1K | |
| 76536 | <1% | 108 | $1K | |
| 88312 | <1% | 66 | $1K | |
| 77065 | Tomosynthesis, mammo | <1% | 90 | $1K |
| 74022 | <1% | 53 | $1K | |
| 59025 | Fetal non-stress test | <1% | 331 | $1K |
| 72141 | <1% | 27 | $987.18 | |
| 96376 | <1% | 45 | $967.95 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 288 | $957.06 |
| 97162 | <1% | 152 | $928.56 | |
| 70360 | <1% | 16 | $840.21 | |
| 77080 | <1% | 78 | $727.86 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 64 | $709.77 |
| 71020 | <1% | 34 | $699.15 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 163 | $684.27 |
| 72131 | <1% | 12 | $628.27 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 85 | $618.36 |
| 29130 | <1% | 127 | $604.36 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 137 | $571.62 |
| 0510 | <1% | 171 | $564.42 | |
| 12002 | <1% | 67 | $531.96 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 62 | $528.82 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 93 | $510.03 |
| 81001 | <1% | 642 | $426.80 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 90 | $423.39 |
| 73660 | <1% | 36 | $386.38 | |
| 82728 | <1% | 215 | $363.82 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 61 | $349.69 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 27 | $327.10 |
| 85651 | <1% | 214 | $291.61 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 122 | $287.70 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 296 | $280.00 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 55 | $277.79 |
| 82570 | <1% | 295 | $241.64 | |
| 74183 | <1% | 12 | $228.02 | |
| A6209 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 49 | $221.74 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 32 | $199.84 |
| 82077 | <1% | 60 | $185.26 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 17 | $181.70 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 41 | $167.28 |
| 83550 | <1% | 207 | $157.18 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 53 | $149.51 |
| 73060 | <1% | 14 | $137.23 | |
| 83540 | <1% | 205 | $129.16 | |
| 73552 | <1% | 13 | $125.93 | |
| 82746 | <1% | 65 | $121.46 | |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 12 | $108.54 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 34 | $97.07 |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 12 | $89.75 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 12 | $85.74 |
| 82607 | <1% | 40 | $81.43 | |
| 94060 | <1% | 27 | $70.69 | |
| 82140 | <1% | 14 | $63.48 | |
| 84132 | <1% | 15 | $40.03 | |
| J2471 | Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg | <1% | 14 | $38.39 |
| 84156 | <1% | 44 | $32.61 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 13 | $25.53 |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 13 | $17.90 |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 15 | $12.52 |
| 0258 | <1% | 29 | $5.78 | |
| 0761 | <1% | 153 | $1.70 | |
| 99072 | <1% | 150 | $0.23 | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | 0% | 260 | $0.00 |
| G0300 | Direct skilled nursing services of a licensed practical nurse (lpn) in the home health or hospice setting, each 15 minutes | 0% | 25 | $0.00 |
| 97802 | 0% | 14 | $0.00 | |
| G0299 | Direct skilled nursing services of a registered nurse (rn) in the home health or hospice setting, each 15 minutes | 0% | 66 | $0.00 |
| 82043 | 0% | 86 | $0.00 | |
| Q4051 | Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) | 0% | 34 | $0.00 |
| 77062 | 0% | 71 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 13 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 30 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPONCE (AKA CARLSON), SUE (SPECIAL PROJECTS)
| Provider | Location | Paid |
|---|---|---|
| Pih Health Downey Hospital | Downey, CA | $25.37M |
| Pih Health Whittier Hospital | La Mirada, CA | $1.53M |
| Pih Health Whittier Hospital | La Mirada, CA | $91K |
| Pih Health Whittier Hospital | Whittier, CA | $12K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.